Replimune Group (REPL) Expected to Release Earnings on Wednesday

Key Points

• Replimune is expected to report Q2 2027 results on Wednesday, October 28, with analysts forecasting a loss of $0.784 per share and revenue of approximately $1 million.
• The company previously reported a quarterly loss of $0.72 per share, missing consensus expectations of $0.69, and analysts project full-year and next-year losses of $2.82 and $2.04 per share, respectively.
• Despite continued losses, analyst sentiment is moderately bullish: Replimune has an average “Moderate Buy” rating and a $12 price target, while shares recently opened at $11.99 after trading between $1.50 and $16.33 over the past year.

Replimune Group (NASDAQ:REPL - Get Free Report) is expected to be posting its Q2 2027 results before the market opens on Wednesday, October 28th. Analysts expect the company to announce earnings of ($0.7840) per share and revenue of $1.00 million for the quarter. Individuals can find conference call details on the company's upcoming Q2 2027 earnings results page for the latest details on the call scheduled for Friday, November 13, 2026 at 9:30 AM ET.

Replimune Group (NASDAQ:REPL - Get Free Report) last posted its earnings results on Friday, August 14th. The company reported ($0.72) EPS for the quarter, missing the consensus estimate of ($0.69) by ($0.03). On average, analysts expect Replimune Group to post ($2.82) EPS for the current fiscal year and ($2.04) EPS for the next fiscal year.

Replimune Group Price Performance

Shares of NASDAQ:REPL opened at $11.99 on Friday. The firm's 50 day moving average is $13.60 and its two-hundred day moving average is $9.86. The firm has a market capitalization of $1.12 billion, a P/E ratio of -3.81 and a beta of 0.93. The company has a current ratio of 5.23, a quick ratio of 5.23 and a debt-to-equity ratio of 1.00. Replimune Group has a 52 week low of $1.50 and a 52 week high of $16.33.

Insider Activity at Replimune Group

In related news, CFO Emily Hill sold 11,448 shares of the firm's stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $12.97, for a total transaction of $148,480.56. Following the transaction, the chief financial officer owned 225,108 shares in the company, valued at $2,919,650.76. This trade represents a 4.84% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Konstantinos Xynos sold 11,447 shares of the business's stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $12.97, for a total value of $148,467.59. Following the sale, the insider directly owned 224,215 shares in the company, valued at approximately $2,908,068.55. The trade was a 4.86% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last three months, insiders have sold 79,124 shares of company stock valued at $1,038,364. Insiders own 5.40% of the company's stock.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on the company. Wedbush upgraded Replimune Group from a "neutral" rating to an "outperform" rating and set a $12.00 price objective for the company in a research report on Friday, August 7th. BMO Capital Markets upgraded Replimune Group from an "underperform" rating to an "outperform" rating and set a $16.00 target price on the stock in a research report on Tuesday, June 30th. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Replimune Group in a research note on Monday, October 5th. Leerink Partners upgraded Replimune Group from a "market perform" rating to an "outperform" rating and boosted their price target for the stock from $11.00 to $17.00 in a research report on Tuesday, August 4th. Finally, JPMorgan Chase & Co. boosted their price target on Replimune Group from $20.00 to $21.00 and gave the stock an "overweight" rating in a research report on Wednesday, August 26th. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has assigned a Hold rating and two have given a Sell rating to the company. According to MarketBeat.com, Replimune Group currently has an average rating of "Moderate Buy" and an average price target of $12.00.

About Replimune Group

Replimune Group, Inc is a clinical-stage biotechnology company developing cancer immunotherapies designed to stimulate the immune system to recognize and attack tumors. The company's approach focuses on oncolytic immunotherapy, using genetically engineered viruses intended to selectively infect and destroy tumor cells while also activating broader antitumor immune responses.

Replimune's lead product candidate is RP1, also known as vusolimogene oderparepvec, an engineered oncolytic herpes simplex virus type 1 designed to replicate within tumors and promote systemic immune activity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.